Literature DB >> 16281260

Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes.

Susan J J Swiggers1, Marianne A Kuijpers, Maartje J M de Cort, H Berna Beverloo, J Mark J M Zijlmans.   

Abstract

Telomeres, nucleoprotein complexes at chromosome ends, protect chromosomes against end-to-end fusion. Previous in vitro studies in human fibroblast models indicated that telomere dysfunction results in chromosome instability. Loss of telomere function can result either from critical shortening of telomeric DNA or from loss of distinct telomere-capping proteins. It is less clear whether telomere dysfunction has an important role in human cancer development in vivo. Acute myeloid leukemia (AML) is a good model to study mechanisms that generate chromosome instability in human cancer development because distinct groups of AML are characterized either by aberrations that theoretically could result from telomere dysfunction (terminal deletions, gains/losses of chromosome parts, nonreciprocal translocations), or aberrations that are unlikely to result from telomere dysfunction (e.g., reciprocal translocations or inversions). Here we demonstrate that AML with multiple chromosome aberrations that theoretically could result from telomere dysfunction is invariably characterized by critically short telomeres. Short telomeres in this group are not associated with low telomerase activity or decreased expression of essential telomeric capping proteins TRF2 and POT1. In contrast, telomerase activity levels are significantly higher in AML with short telomeres. Notably, short telomeres in the presence of high telomerase may relate to significantly higher expression of TRF1, a negative regulator of telomere length. Our observations suggest that, consistent with previous in vitro fibroblast models, age-related critical telomere shortening may have a role in generating chromosome instability in human AML development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16281260     DOI: 10.1002/gcc.20286

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

Review 2.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

Review 3.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

4.  Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia.

Authors:  A M Aalbers; R T Calado; N S Young; C M Zwaan; C Wu; S Kajigaya; E A Coenen; A Baruchel; K Geleijns; V de Haas; G J L Kaspers; T W Kuijpers; D Reinhardt; J Trka; M Zimmermann; R Pieters; V H J van der Velden; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-02-21       Impact factor: 11.528

Review 5.  Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.

Authors:  Adriana Plesa; Isabelle Tigaud; Sandrine Hayette; Christophe Roumier; Xavier Thomas
Journal:  Oncol Ther       Date:  2022-02-07

6.  Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.

Authors:  Beate Vajen; Kathrin Thomay; Brigitte Schlegelberger
Journal:  Cancers (Basel)       Date:  2013-07-04       Impact factor: 6.639

Review 7.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

8.  Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.

Authors:  Justin M Watts; Bogdan Dumitriu; Patrick Hilden; Ashwin Kishtagari; Franck Rapaport; Christina Chen; Jihae Ahn; Sean M Devlin; Eytan M Stein; Raajit Rampal; Ross L Levine; Neal Young; Martin S Tallman
Journal:  Leuk Res       Date:  2016-07-25       Impact factor: 3.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.